OraSure Technologies, Inc. (OSUR)

5.25 +0.03 (+0.57%) At close: 04:00PM EDT

OraSure Technologies, Inc.

220 East First Street
Bethlehem, PA 18015
United States
610 882 1820
https://www.orasure.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 638

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Carrie Eglinton Manner	President, CEO & Director	1.83M	N/A	1975
Mr. Kenneth J. McGrath	Chief Financial Officer	856.5k	N/A	1973
Ms. Kathleen Gallagher Weber	Chief Product Officer	920.43k	9.64k	1967
Ms. Michele Anthony	Senior VP, Chief Accounting Officer, Controller & Assistant Secretary	N/A	N/A	1975
Mr. Rafal Iwasiow Ph.D.	Vice President of Science, Innovation & Technology	N/A	N/A	N/A
Mr. Jason Michael Plagman	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Stefano Taucer	General Counsel & Corporate Secretary	N/A	N/A	N/A
Mr. David A. Rappaport C.F.A.	Senior Vice President Corporate Development, Strategy & Integration	N/A	N/A	N/A
Amy Steigerwalt	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Zachary Wert	Senior Vice President of Global Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

Corporate governance

OraSure Technologies, Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 7; Board: 1; Shareholder rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.